Financial Snapshot
How strong is Cardinal Health's FY2024 financial snapshot?
Strong. The strongest factor is $39B in adjusted free cash flow, and the main concern is GMPD profitability consistency.
For Full Year 2024, Cardinal Health’s snapshot points to solid operating momentum, stronger per-share earnings, and very strong cash generation. The verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For company context, see Mission Statement, Vision, & Core Values (2026) of Cardinal Health, Inc. (CAH).
Next, the $753 non-GAAP diluted EPS and 29% EPS growth deserve the first deeper look because they show how well earnings are converting from sales into shareholder value.
Revenue Quality
Is Cardinal Health revenue growth producing quality earnings?
Mixed. FY2024 revenue growth was 11% to $2268B, and the distribution footprint is broad, but the latest quarter showed weaker reported growth and earnings, so the clearest divergence is between durable demand and uneven quarterly profit conversion.
Revenue growth is only high quality when it repeats, is visible, and turns into operating income, net income, and EPS. Investors compare compatible annual periods because a business can post strong sales from price, mix, or timing while earnings stay flat; that is why Cardinal Health, Inc. (CAH): History, Ownership, Mission, How It Works & Makes Money matters as context for the model behind the numbers.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $2268B, 11%, FY2024 | FY2023 revenue not provided | Organic, driven by recurring pharmaceutical distribution, specialty services, and customer volume | Looks repeatable because Cardinal Health serves 90% of United States hospitals and over 60,000 pharmacies |
| Operating Income | Latest quarter FMP 2026-03-31: $50900M, -2801% | Previous comparable value not provided | Diverged from revenue; operating leverage was not confirmed | Sales alone did not prove stronger earnings quality in the quarter |
| Net Income | Latest quarter FMP 2026-03-31: $39900M, -1529% | Previous comparable value not provided | Weaker than revenue; operating, interest, tax, or unusual-item effects are not broken out here | Final earnings did not clearly confirm the top-line result |
| Diluted EPS | Latest quarter FMP 2026-03-31: $169, -1421% | Previous comparable diluted EPS not provided | Per-share results weakened; share-count effects cannot be separated from the data provided | Shareholders did not get the same strength shown by FY2024 revenue |
How durable is Cardinal Health revenue?
Durability looks solid because demand is tied to hospitals, pharmacies, and ongoing drug flow, but visibility is limited by customer concentration and the concentrated United States pharmaceutical wholesale market.
- Demand Quality: Recurring distribution demand is strong because Cardinal Health serves hospitals and pharmacies continuously, but quarterly timing can still move results.
- Pricing and Volume: The split is only partly visible; Pharmaceutical and Specialty Solutions is shaped by generic program performance and brand-name drug volume from existing customers.
- Diversification: Broad customer reach helps, but concentration in the United States pharmaceutical wholesale market and large customer relationships still create bargaining risk.
That makes profitability and cash conversion the next test.
Cash Quality
Do Cardinal Health's profits convert into cash flow?
Yes. Cardinal Health’s reported profitability is supported by cash generation: FY2024 GAAP operating earnings were $12B, and adjusted free cash flow was $39B. The latest quarter also showed strong earnings and cash growth, but the supplied data do not provide full margin values.
Gross profit is what Cardinal Health keeps after direct product costs, operating income is what remains after operating expenses, and net income is the final profit after interest and taxes. In the latest quarter, revenue was $6094B, gross profit was $250B, operating income was $50900M, and net income was $39900M. For background, Cardinal Health, Inc. (CAH): History, Ownership, Mission, How It Works & Makes Money helps connect those earnings to the business model.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable from supplied data for the latest comparable margin period. | Unavailable from supplied data for the previous comparable margin period. | Latest quarter gross profit growth was 1298%, but no margin percentage was supplied. | Suggests product economics improved, but the margin trend itself cannot be verified here. |
| Operating Margin | Unavailable from supplied data for the latest comparable margin period. | Unavailable from supplied data for the previous comparable margin period. | FY2024 GAAP operating earnings were $12B; latest quarter operating income was $50900M. | Shows operating profit remains meaningful, but scale and efficiency cannot be measured as a margin here. |
| Net Margin | Unavailable from supplied data for the latest comparable margin period. | Unavailable from supplied data for the previous comparable margin period. | Latest quarter interest expense was $10100M, income before tax was $39200M, and income tax expense was $1200M. | Final profit was solid, but the exact margin level cannot be confirmed from the supplied figures alone. |
| Operating Cash Flow | Unavailable; only growth was supplied for 2026-03-31. | Unavailable; only growth was supplied for the prior comparable period. | Operating Cash Flow Growth was 16574%; working-capital detail was not supplied. | Strong cash conversion is implied, and it supports reported earnings better than accounting profit alone. |
| Free Cash Flow | Unavailable; adjusted free cash flow was $39B for FY2024. | Unavailable; no prior comparable free cash flow value was supplied. | Free Cash Flow Growth was 20216%; capex detail was not supplied. | Leaves room for reinvestment, debt service, and shareholder returns if the cash pattern holds. |
What most affects Cardinal Health's cash conversion?
Working capital efficiency appears most important, alongside inflation mitigation, pricing, supply chain optimization, and capex discipline. The supplied data show very strong cash growth, but they do not break out which driver contributed most.
- Main Driver: Working capital efficiency looks structural if sustained, while inflation and pricing benefits may be partly temporary.
- Evidence Gap: The supplied data do not separate inventory, receivables, payables, or capex effects.
- Metric to Monitor: Operating cash flow and free cash flow versus net income.
Liquidity Pressure
Does Cardinal Health have enough liquidity and flexibility to support its obligations and investment needs?
Mixed. Cardinal Health’s main protection is FY2024 Adjusted Free Cash Flow: $39B, but the main concern is sustained cash use from acquisitions, buybacks, dividends, and legal payments while Minus Cash And Cash Equivalents: $394B and Add Total Debt: $892B remain sizable.
Cash alone does not tell the full story. For Cardinal Health, the better test is whether operating cash generation, debt load, asset quality, and required uses of cash can stay balanced after acquisitions, dividends, repurchases, and legal settlements. That mix matters more than any single liquidity figure.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Minus Cash And Cash Equivalents: $394B; recent context: $278B on 2025-12-31, $459B on 2025-09-30, and $387B on 2025-06-30. No current assets or current liabilities were supplied. | Mixed | Cash is useful, but near-term obligations still need ongoing operating cash and careful working-capital control. |
| Total and Net Debt | Add Total Debt: $892B; recent context: $903B on 2025-12-31, $903B on 2025-09-30, and $935B on 2025-06-30. Net debt was not calculated. | Mixed | Debt is manageable only if cash generation stays strong; leverage reduces flexibility for extra spending. |
| Debt Service and Refinancing | FY2024 Adjusted Free Cash Flow: $39B; no interest expense, maturities, or covenant data were supplied. Capital uses also included Share Repurchases: $750M fiscal year 2025 target, Value: $250M ASR, and Dividend: $05047 per share. | Mixed | Cash flow supports debt service today, but refinancing risk cannot be judged fully without maturity detail. |
| Asset Quality | Completed cash acquisitions included Specialty Networks for Purchase Price: $12B and Integrated Oncology Network for Purchase Price: $1115B; the GI Alliance agreement was for Purchase Price: $28B in cash. No goodwill, intangibles, or impairment data were supplied. | Mixed | Acquisition spending can strengthen the business, but it also raises integration and capital-allocation pressure. |
| Liabilities and Equity | Total liabilities and shareholders' equity were not supplied. Legal liquidity context includes a Settlement Amount: $1525M paid in 2024 and the company portion of the $21B total payout over 18 years. | Mixed | Legal cash outflows can reduce flexibility and matter when the company is already using cash for capital returns and acquisitions. |
Which balance-sheet risk matters most for Cardinal Health?
Acquisition and legal cash demands look like the biggest pressure, because they compete directly with dividend, repurchase, and debt needs even while operating cash flow remains solid.
- Current Exposure: FY2024 Adjusted Free Cash Flow: $39B versus Add Total Debt: $892B and cash acquisition spending of $12B, $1115B, and $28B.
- Protection: The strongest buffer is recurring free cash generation, plus recent cash and debt levels that still support ongoing funding capacity.
- Warning Signal: Watch whether buybacks, dividends, acquisitions, and legal payments continue to absorb cash faster than operating cash can replenish it.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. Exploring Cardinal Health, Inc. (CAH) Investor Profile: Who's Buying and Why?
Capital Efficiency
Are Cardinal Health's Reinvestments Improving Capital Efficiency?
Mixed. Cardinal Health appears to have enough internal cash for reinvestment needs, supported by $39B in Adjusted Free Cash Flow, but capital efficiency cannot be fully judged without a supplied ROIC figure.
Return analysis has to account for leverage, asset intensity, capital expenditure, working capital swings, and any outside funding. Cardinal Health’s logistics buildout, automation, and specialty expansion may improve service levels and inventory flow, but the return mix still depends on how much cash those projects absorb versus how much operating cash they generate.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Cannot be tested directly without a verified ROIC figure, but logistics scale and automation should matter if they raise operating efficiency. | Investors need the ROIC trend to judge whether invested capital is creating operating value. |
| ROE and ROA | Non-GAAP Diluted EPS: $753; EPS Growth: 29% for FY2024. | ROE may benefit from leverage, while ROA is more sensitive to asset intensity; EPS growth is supportive but does not replace return metrics. | Shareholder earnings improved, but leverage and asset usage still determine whether returns are high quality. |
| Maintenance and Growth Investment | New 350,000 square-foot Consumer Health Logistics Center in Columbus, Ohio, full operation in Summer 2025; flagship 230,000 square-foot pharmaceutical distribution center in Indianapolis, operational by Fall 2027; Texas at-Home Solutions distribution center with advanced robotics and automation; retrofitting 98% of pharmaceutical cold storage capacity for biologics and specialty drugs. | These projects signal both maintenance and growth spending, but the split is not fully separable from the supplied facts. | Capital is being directed toward service levels, inventory flow, and specialty capability, which could support margin improvement over time. |
| Internal Funding Capacity | Adjusted Free Cash Flow: $39B; shareholder returns also include dividends and share repurchases. | Investment appears internally funded, with shareholder returns competing for the same cash pool. | Strong cash generation supports reinvestment flexibility, but buybacks and dividends reduce cash available for growth. |
Are Cardinal Health's returns on capital sustainable?
Likely, if logistics automation and specialty growth keep lifting cash flow; the biggest weakness would be heavy acquisition spending that fails to earn back its cash outlay. For mission context, see Mission Statement, Vision, & Core Values (2026) of Cardinal Health, Inc. (CAH).
- Operating Source: Logistics scale, robotics, and specialty mix can support margins and asset efficiency.
- Funding Requirement: The largest verified capital need is the distribution network and cold-storage buildout.
- Durability Test: Returns weaken if cash flow softens, acquired earnings disappoint, or working capital and capex keep rising faster than operating profit.
Financial Resilience
How resilient is Cardinal Health, and which warning signs matter most?
Resilience is Mixed. The main buffer is strong cash generation, which supports debt service and capital returns. The most important verified warning sign is GMPD margin pressure, since Cardinal Health is still trying to restore consistent profitability in that segment.
Cardinal Health can still protect liquidity if revenue or margins soften, but the margin mix matters. The Medical Improvement Plan, supply chain resiliency work, and pricing actions show active defense, while the January 01, 2024 segment structure gives clearer visibility. If cash conversion weakens, flexibility would shrink fast.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | GMPD margin compression would hurt operating leverage, reduce earnings and cash flow, and limit debt capacity if medical segment profitability slips again. | Pricing actions, supply chain optimization, and the Medical Improvement Plan support a return to more stable profitability. | Watch for GMPD segment profit moving back toward loss or falling below $15M. |
| Working-Capital or Investment Pressure | Acquisitions, capex, and capital returns can absorb cash even when operations stay healthy, especially if reimbursement or inflation pressure slows conversion. | FY2024 Adjusted Free Cash Flow: $3.9B and $394B in cash and cash equivalents provide internal funding capacity. | Monitor weaker operating cash flow, rising asset growth, or a slower free cash flow trend. |
| Interest or Refinancing Pressure | Higher debt or refinancing costs would reduce free cash flow and narrow financing flexibility, especially after large acquisitions and shareholder returns. | Strong cash generation helps offset funding needs and support maturities. | Watch total debt, interest coverage, and any sign that liquidity is being used faster. |
Which financial warning signs should investors monitor at Cardinal Health?
The top signals are GMPD segment profit, adjusted free cash flow, and total debt. Confirmed deterioration would show up first in weaker GMPD profit and lower cash generation; refinancing pressure is more of a future risk unless debt rises faster than cash.
GMPD Profit Slippage
Cardinal Health reported GMPD Segment Profit of $15M after a loss of $31M a year earlier, but the segment is still being stabilized. The next metric to watch is whether the improvement holds.
Opioid Settlement Cash Outflows
Cardinal Health paid $1525M in 2024 and faces a $700M class-action settlement tied to the broader $21B payout over 18 years. Strong cash generation helps, but adjusted free cash flow is the key monitor.
Acquisition and Capital Return Funding Demand
Cardinal Health has committed large cash uses, including purchase prices of $12B, $1115B, and $28B in cash, plus $750M in share repurchases and a $05047 per share dividend. Total debt is the next metric to watch.
Financial Scorecard
What does Cardinal Health, Inc. financial health mean for investors?
Cardinal Health, Inc. gets a Mixed overall rating. The strongest factor is cash generation, while the weakest factor is legal and segment pressure. The most important condition is whether strong free cash flow can keep covering debt, settlement payments, and capital needs.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | $2268B revenue, 11% revenue growth, $753 Non-GAAP diluted EPS, and 29% EPS growth show scale and per-share earnings, though latest 2026-03-31 growth figures need monitoring. |
| Profitability and Cash | Strong | Adjusted free cash flow of $39B was an all-time high, which supports self-funding, but GMPD margins remain mixed and can still pressure earnings quality. |
| Balance Sheet and Liquidity | Mixed | Cash generation and -$394B cash and cash equivalents support flexibility, but $892B total debt plus acquisitions, legal payments, dividends, and repurchases raise funding demands. |
| Capital Efficiency | Mixed | Specialty, automation, oncology, at-Home Solutions, and logistics investments could improve returns, but acquisition efficiency is not yet proven in the supplied data. |
| Financial Resilience | Mixed | Scale and cash flow help absorb shocks, but GMPD pressure, settlement outflows, inflation, and reimbursement risk remain warning signs. |
- What Supports the Thesis: Strong free cash flow, scale, and earnings growth give Cardinal Health, Inc. room to fund operations and strategy internally.
- What Challenges the Thesis: Debt, settlement payments, and medical profitability pressure could reduce flexibility if cash generation weakens.
- What to Monitor: $39B Adjusted Free Cash Flow, $15M GMPD Segment Profit, $892B Add Total Debt.
For readers building forecasts or scenarios, Exploring Cardinal Health, Inc. (CAH) Investor Profile: Who's Buying and Why? can help connect cash flow strength, balance sheet pressure, and valuation assumptions.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why did Cardinal Health's free cash flow surge?
FY2024 Adjusted Free Cash Flow: $39B reached an all-time company high The supplied data support strong cash generation, but investors should not assume one cause Monitor operating cash flow, capex, working capital, and whether GMPD improvement supports repeatable cash conversion
How do opioid settlements affect liquidity?
Settlements are a real cash-use risk Cardinal Health paid Settlement Amount: $1525M in 2024 and continues its portion of the $21B total payout over 18 years Strong free cash flow helps, but legal payments still compete with acquisitions, dividends, and repurchases
Does GMPD weakness threaten Cardinal Health margins?
GMPD remains the main margin watch item Q3 2024 GMPD Segment Profit: $15M improved from a loss of $31M in the prior year quarter, but the Medical Improvement Plan shows management is still focused on inflation mitigation, supply chain resiliency, and consistent profitability
What does specialty flywheel mean for returns?
The Specialty Flywheel connects distribution, physician practice platforms, oncology services, and biopharma services It may improve mix and capital efficiency, but investors should verify results through operating earnings, cash flow, acquisition integration, and return metrics rather than assuming higher returns automatically
Is Cardinal Health's debt level manageable?
FMP Enterprise Values 2026-03-31 show Minus Cash And Cash Equivalents: $394B and Add Total Debt: $892B FY2024 cash generation supports flexibility, but debt should be monitored after cash acquisitions, legal payments, dividends, and share repurchases